Literature DB >> 26474434

Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.

Ki Byung Song1, Song Cheol Kim, Ji Hun Kim, Dong-Wan Seo, Seung-Mo Hong, Kwang-Min Park, Dae Wook Hwang, Jae Hoon Lee, Young-Joo Lee.   

Abstract

OBJECTIVES: Studies on the expression of somatostatin receptor (SSTR) subtypes in pancreatic neuroendocrine tumors (PNETs) are rare. The aim of this study was to determine the expression of the SSTR subtypes via immunohistochemistry analyses and assess the correlation between SSTR subtype expression and prognosis.
METHODS: We examined 199 patients with PNET who underwent surgical resection between January 1995 and December 2010 at the Asan Medical Center. For all cases, medical records, including demographic data, clinical symptoms, radiological findings, postoperative treatment outcomes, and expression of SSTR subtypes, were carefully reviewed.
RESULTS: In total, 162 (81.4%) PNETs expressed more than 1 SSTR subtype. Functioning PNET expressed significantly more SSTR subtypes, compared to nonfunctioning PNET. The SSTR2(+) and SSTR5(+) groups had better prognosis than the SSTR2(-) (P = 0.009) and SSTR5(-) groups (P = 0.03), respectively. In the grade 2 PNET of 2010 World Health Organization classification, the SSTR(+) group had better prognosis than SSTR(-) group.
CONCLUSIONS: The expression of SSTR 2 and 5 were related with good prognosis of PNET. In World Health Organization grade 2 PNET, the SSTR(+) group had better prognosis than SSTR(-) group. The SSTR expression(+) by immunohistochemistry might be related with good prognosis of the patients with surgically resected PNET.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26474434     DOI: 10.1097/MPA.0000000000000493

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.

Authors:  Ylberta Kajtazi; Daniel Kaemmerer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-26       Impact factor: 4.553

3.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

4.  Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.

Authors:  Susann Stollberg; Daniel Kämmerer; Elisa Neubauer; Stefan Schulz; Ingrid Simonitsch-Klupp; Barbara Kiesewetter; Markus Raderer; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

5.  Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Authors:  Romain Appay; Emeline Tabouret; Mehdi Touat; Catherine Carpentier; Carole Colin; François Ducray; Ahmed Idbaih; Karima Mokhtari; Emmanuelle Uro-Coste; Caroline Dehais; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2018-09-07       Impact factor: 7.801

6.  Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.

Authors:  Julia Wanek; Martin Gaisberger; Marlena Beyreis; Christian Mayr; Katharina Helm; Florian Primavesi; Tarkan Jäger; Pietro Di Fazio; Martin Jakab; Andrej Wagner; Daniel Neureiter; Tobias Kiesslich
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

7.  Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin.

Authors:  Rebekka Mai; Daniel Kaemmerer; Tina Träger; Elisa Neubauer; Jörg Sänger; Richard P Baum; Stefan Schulz; Amelie Lupp
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

8.  Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.

Authors:  Rachael Guenter; Tolulope Aweda; Danilea M Carmona Matos; Samuel Jang; Jason Whitt; Yi-Qiang Cheng; X Margaret Liu; Herbert Chen; Suzanne E Lapi; Renata Jaskula-Sztul
Journal:  Surgery       Date:  2019-10-16       Impact factor: 3.982

Review 9.  Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.

Authors:  Yuheng Hu; Zeng Ye; Fei Wang; Yi Qin; Xiaowu Xu; Xianjun Yu; Shunrong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

10.  Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors.

Authors:  G Lamberti; C Ceccarelli; N Brighi; I Maggio; D Santini; C Mosconi; C Ricci; G Biasco; D Campana
Journal:  Gastroenterol Res Pract       Date:  2017-10-29       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.